Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Zoetis (ZOE) Stock Price & Analysis

0 Followers

ZOE Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 27.88B
Enterprise Value
CHF 36.45B
Total Cash (Recent Filing)
CHF 1.53B
Total Debt (Recent Filing)
CHF 9.24B
Price to Earnings (P/E)
14.0
Beta
N/A
Next Earnings
Feb 16, 2027 (Est.)
EPS Estimate
1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Profitability And Cash Generation

Zoetis combines high margins with substantial operating and free cash flow, indicating that earnings are strongly cash-backed. This financial capacity supports research, commercial investment, dividends, and repurchases while helping the company sustain its competitive position through normal market cycles.

Diversified Animal Health Portfolio

Growth across livestock, international markets, and diagnostics provides meaningful diversification beyond pressured U.S. companion-animal products. This breadth can reduce dependence on any single franchise, support recurring customer relationships, and create multiple avenues for durable expansion.

Pipeline And Product Innovation

The planned launches and broader pipeline provide potential lifecycle extensions and new growth categories in animal health. Although contribution is expected to build gradually, continued approvals and innovation can refresh established franchises and support longer-term revenue durability.

Bears Say

Companion Animal And Dermatology Pressure

Companion-animal weakness, especially dermatology competition and Apoquel share loss, is affecting a strategically important product area. Persistent pressure could restrain revenue and earnings growth until newer products scale and the company stabilizes market share.

High Financial Leverage

Debt materially exceeds the equity base, reducing balance-sheet flexibility relative to the company’s otherwise strong profitability. If growth remains soft or financing costs stay elevated, leverage could constrain investment choices and increase sensitivity to weaker operating performance.

Demand And Margin Headwinds

Recent revenue contraction and lower margins indicate that demand, product mix, and competitive pricing are pressuring near-term earnings quality. Continued clinic-visit weakness and affordability concerns could prolong these headwinds before pipeline launches materially contribute.

Zoetis News

ZOE FAQ

What is Zoetis’s market cap?
Zoetis’s market cap is CHF27.88B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s next earnings report is estimated for Feb 16, 2027 (not yet confirmed), which is in 96 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Nov 05, 2026. The company reported CHF1.444 earnings per share for the quarter, beating the consensus estimate of CHF1.248 by CHF0.196.
Is Zoetis overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Zoetis pay dividends?
Zoetis does not currently pay dividends.
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.00.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of CHF1.444 in its last earnings report, beating expectations of CHF1.248. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Zoetis?
Hedge funds hold Zoetis shares: the largest hedge-fund position in Zoetis is 567,771,961 shares, and hedge funds increased their holdings by 4.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology